EBM

Eastwood Bio-medical Canada Inc.

TSXV

Add Alert

EBM

Eastwood Bio-medical Canada Inc.

TSXV

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Claude233

01/08/19 6:53 PM

Post #25

EASTWOOD BIO-MEDICAL CANADA INC.
#1130 - 4871 Shell Road
Richmond, British Columbia
V6X 3Z6

TSX-V: EBM

NEWS RELEASE

Eastwood Bio-Medical Canada Inc. Reflects on Entry into Asian Market

January 2, 2019 – Richmond, British Columbia – Eastwood Bio-Medical Canada Inc. (TSX-V: EBM) (the “Company”) is pleased to announce that the Company has continued to fulfill initial shipments to an Asian distributor. The Company published preliminary announcements concerning Asian exports in June and October of this year.

Yunji Kim, President and CEO, commented, “We announced on October 1, 2018 the shipment of products to Asia valuing about $550,000 in consumer retail value. Since then, we estimate to have shipped out products totaling about $850,000 in retail value. In previous years there were practically no such shipments. We will be able to detail more accurate numbers once our annual audit and quarterly review have concluded. Asian demand has been rising sharply in the past few months. I must caution, however, recent shipments may not be an indication of what long term trends may be.”

About Eastwood Bio-Medical Canada, Inc.:
The Company is a Vancouver based company whose Eleotin brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.

Eleotin was initially developed by the scientists at the Julia McFarlane Diabetes Research Center (JMDRC) at the University of Calgary in Alberta, Canada. The JMDRC is a leader in research on Type I and Type II diabetes. After the initial development by the JMDRC, research and development were continued by Eastwood Bio-Medical Research Inc., the Company, and other institutions around the world, including Tsinghua University of the People’s Republic of China. Eleotin products have been endorsed by thousands of doctors and medical associations around the globe, and authorized by Advertising Standards Canada (ASC) to be marketed as the
‘World’s #1 Doctor Recommended Natural Source Healthy Blood Glucose Promoting Product
available in Canada.’

More information on Eastwood Bio-Medical Canada Inc., can be found on the website www.eleotin.ca.

For further information, please contact:

Eastwood Bio-Medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
Telephone: (604) 247-2100

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. There is no assurance that the new products will produce the revenue increase the Company expects. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Claude233

12/19/18 4:25 PM

Post #24

EASTWOOD BIO-MEDICAL CANADA INC.
#1130 - 4871 Shell Road
Richmond, British Columbia
V6X 3Z6

TSX-V: EBM

NEWS RELEASE

Eastwood Bio-Medical Canada Inc. Announces Over One Hundred Eleotin Discussion Groups

December 19, 2018 – Richmond, British Columbia – Eastwood Bio-Medical Canada Inc. (TSX-V: EBM) (the “Company”) is pleased to announce that over one hundred discussion groups have been established in Asia to discuss Eleotin products. Independent of the Company, these self-study groups meet regularly, about once a week, to study Eleotin products, share personal experiences, and study further the mechanics and effects of Eleotin.

Yunji Kim, President and CEO, commented, “At the beginning of this year, there were only two such groups meeting regularly. Now, the number of groups exceeds one hundred. The groups prefer to keep themselves at an intimate size, about five to fifteen people each. But some groups have ballooned to host up to fifty people regularly on a weekly basis. As more people experience Eleotin, they have become eager to share their stories and learn how they can further work with Eleotin to improve their lives. It is not uncommon for over one hundred people to attend a meeting at times. While these groups operate independently of our company, it is heartwarming to see how Eleotin can touch so many lives.”

About Eastwood Bio-Medical Canada, Inc.:
The Company is a Vancouver based company whose Eleotin brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.

Eleotin was initially developed by the scientists at the Julia McFarlane Diabetes Research Center (JMDRC) at the University of Calgary in Alberta, Canada. The JMDRC is a leader in research on Type I and Type II diabetes. After the initial development by the JMDRC, research and development were continued by Eastwood Bio-Medical Research Inc., the Company, and other institutions around the world, including Tsinghua University of the People’s Republic of China. Eleotin products have been endorsed by thousands of doctors and medical associations around the globe, and authorized by Advertising Standards Canada (ASC) to be marketed as the
‘World’s #1 Doctor Recommended Natural Source Healthy Blood Glucose Promoting Product
available in Canada.’

More information on Eastwood Bio-Medical Canada Inc., can be found on the website www.eleotin.ca.

For further information, please contact:

Eastwood Bio-Medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
Telephone: (604) 247-2100

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. There is no assurance that the new products will produce the revenue increase the Company expects. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Claude233

12/19/18 4:25 PM

Post #23

EASTWOOD BIO-MEDICAL CANADA INC.
#1130 - 4871 Shell Road
Richmond, British Columbia
V6X 3Z6

TSX-V: EBM

NEWS RELEASE

Eastwood Bio-Medical Canada Inc. Begins Commercial Production of Natural Statin Product

December 18, 2018 – Richmond, British Columbia – Eastwood Bio-Medical Canada Inc. (TSX-V: EBM) (the “Company”) is pleased to announce that the Company has begun commercial production of a natural statin products. Statins, or HMG CoA reductase inhibitors, are the main active components of the most popular and effective products on the market for cholesterol control. Over the years, pharmaceutical companies have used statins in some of their best-selling drugs that prevent cardiovascular diseases such as heart attacks and strokes.

The Company’s new product, Eleotin R-Square C1 Formula is made entirely of natural ingredients such as red yeast rice, known to have the same cholesterol-lowering effects but with fewer potential side effects. Published studies have also shown the possibilities of other health benefits such as boosting immune systems and anti-hypertension effects.

Yunji Kim, President and CEO, commented, “We have been aggressively researching and developing natural sourced solutions for some of the biggest health problems out there. With our state of the art facilities ready and capable of producing these solutions on a mass scale, I believe we are ready to serve our fast growing clientele.”

About Eastwood Bio-Medical Canada, Inc.:
The Company is a Vancouver based company whose Eleotin brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.

Eleotin was initially developed by the scientists at the Julia McFarlane Diabetes Research Center (JMDRC) at the University of Calgary in Alberta, Canada. The JMDRC is a leader in research on Type I and Type II diabetes. After the initial development by the JMDRC, research and development were continued by Eastwood Bio-Medical Research Inc., the Company, and other institutions around the world, including Tsinghua University of the People’s Republic of China. Eleotin products have been endorsed by thousands of doctors and medical associations around the globe, and authorized by Advertising Standards Canada (ASC) to be marketed as the
‘World’s #1 Doctor Recommended Natural Source Healthy Blood Glucose Promoting Product
available in Canada.’

More information on Eastwood Bio-Medical Canada Inc., can be found on the website www.eleotin.ca.

For further information, please contact:

Eastwood Bio-Medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
Telephone: (604) 247-2100

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. There is no assurance that the new products will produce the revenue increase the Company expects. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Claude233

12/19/18 4:24 PM

Post #22

EASTWOOD BIO-MEDICAL CANADA INC.
#1130 - 4871 Shell Road
Richmond, British Columbia
V6X 3Z6

TSX-V: EBM

NEWS RELEASE

Eastwood Bio-Medical Canada Inc. Announces Launch of Contract Manufacturing Operations

November 15, 2018 – Richmond, British Columbia – Eastwood Bio-Medical Canada Inc. (TSX-V: EBM) (the “Company”) is pleased to announce that the Company has begun contract manufacturing operations.

Yunji Kim, President and CEO, commented, “With the acquisition of manufacturing facilities finalized, we have inherited significant custom manufacturing clients, including a multi-year manufacturing contract.” The Company previously announced the acquisition of Good Manufacturing Practices (GMP) compliant, Health Canada and foreign site licensed facilities. Yunji Kim continued, “We are at very preliminary juncture. It is too early to know how significant and profitable our contract manufacturing operations will be. But we are excited about the addition of new sources of revenue streams, and further growing and developing our facilities.”

About Eastwood Bio-Medical Canada, Inc.:
The Company is a Vancouver based company whose Eleotin brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.

Eleotin was initially developed by the scientists at the Julia McFarlane Diabetes Research Center (JMDRC) at the University of Calgary in Alberta, Canada. The JMDRC is a leader in research on Type I and Type II diabetes. After the initial development by the JMDRC, research and development were continued by Eastwood Bio-Medical Research Inc., the Company, and other institutions around the world, including Tsinghua University of the People’s Republic of China. Eleotin products have been endorsed by thousands of doctors and medical associations around the globe, and authorized by Advertising Standards Canada (ASC) to be marketed as the
‘World’s #1 Doctor Recommended Natural Source Healthy Blood Glucose Promoting Product
available in Canada.’

More information on Eastwood Bio-Medical Canada Inc., can be found on the website www.eleotin.ca.

For further information, please contact:

Eastwood Bio-Medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
Telephone: (604) 247-2100

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. There is no assurance that the new products will produce the revenue increase the Company expects. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Claude233

12/19/18 4:23 PM

Post #21

EASTWOOD BIO-MEDICAL CANADA INC.
#1130 - 4871 Shell Road
Richmond, British Columbia
V6X 3Z6

TSX-V: EBM

NEWS RELEASE

Eastwood Bio-Medical Canada Inc. Announces Unaudited Quarterly Revenue Estimates

November 15, 2018 – Richmond, British Columbia – Eastwood Bio-Medical Canada Inc. (TSX-V: EBM) (the “Company”) is pleased to announce that the Company estimates from initial unaudited calculations a revenue growth of roughly over 350% for Q4, ending October 31, 2018.

Yunji Kim, President and CEO, commented, “We must caution that it is still too early to conclude this recent growth is any indication of any long-term trend. Also, the upcoming annual audit may correct our current estimate.”

About Eastwood Bio-Medical Canada, Inc.:
The Company is a Vancouver based company whose Eleotin brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.

Eleotin was initially developed by the scientists at the Julia McFarlane Diabetes Research Center (JMDRC) at the University of Calgary in Alberta, Canada. The JMDRC is a leader in research on Type I and Type II diabetes. After the initial development by the JMDRC, research and development were continued by Eastwood Bio-Medical Research Inc., the Company, and other institutions around the world, including Tsinghua University of the People’s Republic of China. Eleotin products have been endorsed by thousands of doctors and medical associations around the globe, and authorized by Advertising Standards Canada (ASC) to be marketed as the
‘World’s #1 Doctor Recommended Natural Source Healthy Blood Glucose Promoting Product
available in Canada.’

More information on Eastwood Bio-Medical Canada Inc., can be found on the website www.eleotin.ca.

For further information, please contact:

Eastwood Bio-Medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
Telephone: (604) 247-2100

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. There is no assurance that the new products will produce the revenue increase the Company expects. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Claude233

12/19/18 4:22 PM

Post #20

EASTWOOD BIO-MEDICAL CANADA INC.
#1130 - 4871 Shell Road
Richmond, British Columbia
V6X 3Z6

TSX-V: EBM

NEWS RELEASE

Eastwood Bio-Medical Canada Inc. Begins Initial Discussions with Autoimmune Disease Experts

November 14, 2018 – Richmond, British Columbia – Eastwood Bio-Medical Canada Inc. (TSX-V: EBM) (the “Company”) is pleased to announce that the Company has begun exploring the possibility of eventually developing products for patients of autoimmune disorders and has begun initial discussions with experts on autoimmune diseases.

“Autoimmune diseases” is a term that describes a group of diseases where the body’s immune system attacks its own tissues. Examples of autoimmune diseases include: rheumatoid arthritis, lupus, inflammatory bowel disease (IBD), multiple sclerosis (MS), Type 1 diabetes mellitus, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, psoriasis, Graves' disease, Hashimoto's thyroiditis, myasthenia gravis, and vasculitis.

The Company has recently begun accumulating an increasing number of anecdotal cases from patients of autoimmune diseases whose conditions have significantly improved both in the short and long terms after using our products. There have also been numerous reports from clients about improvements regarding their inflammation conditions generally.

Yunji Kim, President and CEO, commented, “We are intrigued and encouraged by these anecdotes. We have also noted the publication of studies and articles exploring the relationship between insulin resistance, blood glucose levels, and some autoimmune diseases. We believe it is justifiable and timely to look into the possibility of developing products that help consumers with autoimmune disorders. Continuing our long history of working with global leaders in science and medicine, we have started initial discussions with experts in this field.

However, it is important to note that at this point we have only anecdotal testimonials from clients relaying their own individual experiences. Autoimmune diseases are serious medical conditions, and we make no claims or suggestions regarding any effect our products may have. Patients, regardless of their condition, should always consult with their doctors before starting any new regime. There will have to be a long and uncertain process before we can scientifically ascertain any effect our products may have on autoimmune patients.”

About Eastwood Bio-Medical Canada, Inc.:
The Company is a Vancouver based company whose Eleotin brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.

Eleotin was initially developed by the scientists at the Julia McFarlane Diabetes Research Center (JMDRC) at the University of Calgary in Alberta, Canada. The JMDRC is a leader in research on Type I and Type II diabetes. After the initial development by the JMDRC, research and development were continued by Eastwood Bio-Medical Research Inc., the Company, and other institutions around the world, including Tsinghua University of the People’s Republic of China. Eleotin products have been endorsed by thousands of doctors and medical associations around the globe, and authorized by Advertising Standards Canada (ASC) to be marketed as the
‘World’s #1 Doctor Recommended Natural Source Healthy Blood Glucose Promoting Product
available in Canada.’

More information on Eastwood Bio-Medical Canada Inc., can be found on the website www.eleotin.ca.

For further information, please contact:

Eastwood Bio-Medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
Telephone: (604) 247-2100

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. There is no assurance that the new products will produce the revenue increase the Company expects. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Claude233

10/18/18 6:32 PM

Post #19

EASTWOOD BIO-MEDICAL CANADA INC.

NEWS RELEASE

EASTWOOD BIO-MEDICAL CANADA INC. UNAWARE OF ANY MATERIAL CHANGE

FOR IMMEDIATE RELEASE

October 18, 2018 – Richmond, British Columbia – At the request of IIROC, Eastwood Bio-medical Canada Inc. (TSX-V: EBM) (the “Company”) wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent market activity.

The Company is a Vancouver based biotechnology company whose Eleotin® brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain assumptions, estimates, and other forward-looking statements regarding future events. Such forward-looking statements involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.

For further information, please contact:
Eastwood Bio-medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
Telephone: (604)-247-2100

www.eleotin.ca

Claude233

10/11/18 7:00 PM

Post #18

EASTWOOD BIO-MEDICAL CANADA INC.
#1130 - 4871 Shell Road
Richmond, British Columbia
V6X 3Z6

TSX-V: EBM

NEWS RELEASE

Eastwood Bio-Medical Canada Inc. Begins Discussions for Manufacturing Products for Health Food Companies
October 11, 2018 – Richmond, British Columbia – Eastwood Bio-Medical Canada Inc. (TSX-V: EBM) (the “Company”) is pleased to announce the Company has begun discussing manufacturing for several health food companies, including those with a wide presence in North America. The Company expects its facilities to generate manufacturing revenue from these sources beginning November 2018. It is expected that the Company will produce for them an estimated 12 million capsules, 50,000 bottles of capsules, 100,000 jars of functional food powder, as well as 500,000 blister packs a year. The Company expects to update these figures as the true capacity of the new facilities become clear.
The Company announced this past April that it was exercising its right to purchase the manufacturing assets of Eastwood Bio-Medical Research Inc. (EBMR). EBMR’s manufacturing facilities holds a site licence granted by Health Canada in accordance to General Manufacturing Practices (GMP) requirements. The facilities are currently capable of producing up to 3 million capsules and packaging 10,000 bottles per day. The facilities are also capable of packaging powdered natural health products such as meal replacement foods and supplement sachets. These capacities are expected to increase as the new facilities go through initial break-in periods.
Yunji Kim, President and CEO, commented, “We can only roughly estimate today the true long-term capacity of our new facilities, and our capability to maintain contract manufacturing clients. However, we do know that we can offer high quality manufacturing services with a practice dedicated to an efficiency unique to the market. We estimated that the facilities could yield possible savings of up to $7 million in manufacturing costs, as well as allow us to research and develop additional products, and fast track to the market launch of new products in the Company’s pipeline. The acquisition of additional streams of revenue would be a further example how the facilities could contribute to our Company’s growth.”
About Eastwood Bio-Medical Canada, Inc.:
The Company is a Vancouver based company whose Eleotin brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.

Eleotin was initially developed by the scientists at the Julia McFarlane Diabetes Research Center (JMDRC) at the University of Calgary in Alberta, Canada. The JMDRC is a leader in research on the cause, cure, and prevention of Type I and Type II diabetes. After the initial development by the JMDRC, research and development were continued by Eastwood Bio-Medical Research Inc., the Company, and other institutions around the world, including Tsinghua University of the People’s Republic of China. Eleotin products have been endorsed by thousands of doctors and diabetes associations around the globe.

More information on Eastwood Bio-Medical Canada Inc., can be found on the website www.eleotin.ca.
For further information, please contact:

Eastwood Bio-Medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
Telephone: (604) 247-2100

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. There is no assurance that the new products will produce the revenue increase the Company expects. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Claude233

09/24/18 7:49 PM

Post #17

EASTWOOD BIO-MEDICAL CANADA INC.
#1130 - 4871 Shell Road
Richmond, British Columbia
V6X 3Z6

TSX-V: EBM

NEWS RELEASE

Eastwood Bio-Medical Canada Announces Recent Progress of Eleotin® Products in Asia
September 24, 2018 – Richmond, British Columbia – Eastwood Bio-medical Canada Inc. (TSX-V: EBM) (the “Company”) is pleased to announce the progress of Eleotin® products in Asia. The Company announced entering binding terms with an Asian distribution company on June 28, 2018. On September 10, 2018, the Company announced the successful acquisition of product approvals from the Ministry of Food and Drug Safety of South Korea, and initial shipments of approved products valuing at about $450,000 in consumer retail value. Besides these shipments of capsuled products, the Company has also shipped nutraceutical tea products valued at about $100,000 in consumer retail value. Initial distributor reports showed Eleotin® sales of over $30,000 generated between September 20 and 24, 2018.
The Company is also pleased to announce the publication and distribution of a new book, “Notes on Prayer and Healing,” penned by the Company’s initial founder, Dr. Youngsoo Kim. Printed and circulated in Asia, the Company has fulfilled an initial order of 2,000 copies to a distributor. Revenues from book sales are expected to be reflected in the Company’s fourth quarter statements.
The Company cautions that initial distributor reports are not subject to audit, and may not be any indication of future growth.
Yunji Kim, President and CEO commented, “We entered a highly competitive market with some of the most educated and critical consumers in the world. We are still at a developmental stage in establishing ourselves in the Korean market. Naturally, we are encouraged by the result from the past few days. But we do know there is still a lot more work to do, and more time needs to pass until we know what we can truly accomplish in this market.”
About Eastwood Bio-Medical Canada, Inc.:
The Company is a Vancouver based company whose Eleotin® brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.

Eleotin® was initially developed by the scientists at the Julia McFarlane Diabetes Research Center (JMDRC) at the University of Calgary in Alberta, Canada. The JMDRC is a leader in research on the cause, cure, and prevention of Type I and Type II diabetes. After the initial development by the JMDRC, research and development were continued by Eastwood Bio-medical Research Inc., the Company, and other institutions around the world, including Tsinghua University of the People’s Republic of China. Eleotin® products have been endorsed by thousands of doctors and diabetes associations around the globe.

More information on Eastwood Bio-Medical Canada Inc., can be found on the website www.eleotin.ca.
For further information, please contact:

Eastwood Bio-Medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
Telephone: (604) 247-2100

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. There is no assurance that the new products will produce the revenue increase the Company expects. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Claude233

09/10/18 7:32 PM

Post #16

EASTWOOD BIO-MEDICAL CANADA INC.
#1130 - 4871 Shell Road
Richmond, British Columbia
V6X 3Z6

TSX-V: EBM

NEWS RELEASE

Eastwood Bio-medical Canada Inc. Announces Product Approvals from the South Korean Government and Initial Shipment of Products to Korea

September 10, 2018 – Richmond, British Columbia – Eastwood Bio-medical Canada Inc. (TSX-V: EBM) (the “Company”) is pleased to announcement the successful acquisition of product approvals from the Ministry of Food and Drug Safety, of South Korea. As a result of these approvals, initial shipments of products valuing at about $450,000 in consumer retail value were sent to South Korea during the Company’s third quarter.
Yunji Kim, President and CEO commented, “The South Korean government has some of the highest and most stringent standards anywhere. The South Korean market is also one of the most competitive and savvy consumer markets in the world. We are very proud and excited about our recent foray into it. Eleotin® products can now be found in major Korean online shopping sites such as Gmarket, Auction, 11Street, Interpark and Naver.”

About Eastwood Bio-Medical Canada, Inc.:
The Company is a Vancouver based biotechnology company whose Eleotin® brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.

Eleotin® was initially developed by the scientists at the Julia McFarlane Diabetes Research Center (JMDRC) at the University of Calgary in Alberta, Canada. The JMDRC is a leader in research on the cause, cure, and prevention of Type I and Type II diabetes. After the initial development by the JMDRC, research and development were continued by Eastwood Bio-medical Research Inc., the Company, and other institutions around the world, including Tsinghua University of the People’s Republic of China. Eleotin® products have been endorsed by thousands of doctors and diabetes associations around the globe.

More information on Eastwood Bio-Medical Canada Inc., can be found on the website www.eleotin.ca.
For further information, please contact:

Eastwood Bio-Medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
Telephone: (604) 247-2100
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. There is no assurance that the new products will produce the revenue increase the Company expects. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Claude233

09/06/18 3:18 PM

Post #15

Eastwood Bio-medical Canada Inc. Introduces New Cannabis and Cholesterol Products

September 5, 2018 – Richmond, British Columbia – Eastwood Bio-medical Canada Inc. (TSX-V: EBM) (the “Company”) is pleased to announce Health Canada has granted further new Natural Product Numbers (NPNs) for the following products:
Eleotin HepaBene, for liver health.
Eleotin Solomon, a cannabis product for improving mental performance.
Eleotin Philosophy, a cannabis product for enhancing cognitive functions.
Eleotin R-square C1 Formula, for lowering cholesterol.

Yunji Kim, President and CEO, commented, “It’s an exciting time for us. We are branching out into providing the market with novel formulations made with the finest ingredients in the market. We have been aggressively adding to our portfolio of products, and look forward to serving a wider target market.”
About Eastwood Bio-Medical Canada, Inc.:
The Company is a Vancouver based biotechnology company whose Eleotin® brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.

Eleotin® was initially developed by the scientists at the Julia McFarlane Diabetes Research Center (JMDRC) at the University of Calgary in Alberta, Canada. The JMDRC is a leader in research on the cause, cure, and prevention of Type I and Type II diabetes. After the initial development by the JMDRC, research and development were continued by Eastwood Bio-medical Research Inc., the Company, and other institutions around the world, including Tsinghua University of the People’s Republic of China. Eleotin® products have been endorsed by thousands of doctors and diabetes associations around the globe.

More information on Eastwood Bio-Medical Canada Inc., can be found on the website www.eleotin.ca.
For further information, please contact:

Eastwood Bio-Medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
Telephone: (604) 247-2100
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forwardlooking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. There is no assurance that the new products will produce the revenue increase the Company expects. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Claude233

09/06/18 3:13 PM

Post #14

EASTWOOD BIO-MEDICAL CANADA INC. UNAWARE OF ANY MATERIAL CHANGE

FOR IMMEDIATE RELEASE

August 27, 2018 – Richmond, British Columbia – At the request of IIROC, Eastwood Bio-medical Canada Inc. (TSX-V: EBM) (the “Company”) wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.

The Company is a Vancouver based biotechnology company whose Eleotin® brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain assumptions, estimates, and other forward-looking statements regarding future events. Such forward-looking statements involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.

For further information, please contact:
Eastwood Bio-medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
Telephone: (604)-247-2100

www.eleotin.ca

Claude233

09/06/18 3:11 PM

Post #13

EASTWOOD BIO-MEDICAL CANADA INC. UNAWARE OF ANY MATERIAL CHANGE

FOR IMMEDIATE RELEASE

August 20, 2018 – Richmond, British Columbia – At the request of IIROC, Eastwood Bio-medical Canada Inc. (TSX-V: EBM) (the “Company”) wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.

The Company is a Vancouver based biotechnology company whose Eleotin® brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain assumptions, estimates, and other forward-looking statements regarding future events. Such forward-looking statements involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.

For further information, please contact:
Eastwood Bio-medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
Telephone: (604)-247-2100

www.eleotin.ca

Claude233

08/09/18 4:21 PM

Post #12

EASTWOOD BIO-MEDICAL CANADA INC.
#1130 - 4871 Shell Road
Richmond, British Columbia
V6X 3Z6

TSX-V: EBM

NEWS RELEASE

Eastwood Bio-medical Canada Inc. Introduces New Product For
Memory and Cognitive Function in Adults

August 9, 2018 – Richmond, British Columbia – Eastwood Bio-medical Canada Inc. (TSX-V: EBM) (the “Company”) is pleased to announce the introduction of nine new products. Since the Company last announced the introduction of new products on May 4, 2018, Health Canada has granted further nine new Natural Product Numbers (NPNs), including one for a product named Eleotin® Neuro Formula. Eleotin® Neuro Formula helps to enhance cognitive function and memory in adults.
Yunji Kim, President and CEO, commented, “We are particularly pleased with this development. Directly addressing and providing solutions for memory loss and dementia opens up significant additional new target markets.
Scientific institutions like the National Institute of Health (NIH), and numerous media outlets have reported that cognitive diseases such as Alzheimer’s are another form of diabetes, going as far as calling the condition Type III diabetes. Our own products have long been praised as the ‘World’s #1 Doctor Recommended Natural Source Healthy Blood Glucose Promoting Product available in Canada.’ Accordingly, it was presumed that our company’s core technologies were highly likely to help patients showing symptoms of cognitive and memory degeneration. Several hundred clients have already provided testimonials with anecdotes about Eleotin® products significantly improving their cognitive health. With our recent approval, we can officially start providing the market with a safe product specifically for cognitive health.”

About Eastwood Bio-Medical Canada, Inc.:
The Company is a Vancouver based biotechnology company whose Eleotin® brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.

Eleotin® was initially developed by the scientists at the Julia McFarlane Diabetes Research Center (JMDRC) at the University of Calgary in Alberta, Canada. The JMDRC is a leader in research on the cause, cure, and prevention of Type I and Type II diabetes. After the initial development by the JMDRC, research and development were continued by Eastwood Bio-medical Research Inc., the Company, and other institutions around the world, including Tsinghua University of the People’s Republic of China. Eleotin® products have been endorsed by thousands of doctors and diabetes associations around the globe.

More information on Eastwood Bio-Medical Canada Inc., can be found on the website www.eleotin.ca.

For further information, please contact:

Eastwood Bio-Medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
Telephone: (604) 247-2100

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Claude233

08/09/18 4:18 PM

Post #11

EASTWOOD BIO-MEDICAL CANADA INC.
#1130 - 4871 Shell Road
Richmond, BC V6X 3Z6

TSX-V: EBM

NEWS RELEASE

Eastwood Bio-Medical Canada to Settle Loan Owed by Eastwood Bio-Medical Research Inc.

August 9, 2018 – Vancouver, British Columbia – Eastwood Bio-Medical Canada Inc. (TSX-V: EBM) (the “Company”) announces that it proposes to settle the remaining outstanding balance of a loan (the “Loan”) in the amount of $1,140,700 (the “Loan Balance”) owed by Eastwood Bio-Medical Research Inc. (“EBMR”) under a loan agreement dated June 24, 2016 (the “Loan Agreement”).

Subject to approval by the TSX Venture Exchange, the Company proposes to settle the Loan Balance owed by EBMR in the following manner:
• The transfer of certain assets in and improvements to premises owned by EBMR and in which the Company’s natural health products are produced, pursuant to a Bill of Sale for Construction Agreement to be entered into between the Company and EBMR. The purchase price for these assets will be $265,000 and will be settled by the forgiveness by the Company of $265,000 of the Loan Balance owed by EBMR.
• Leasing commercial space in premises owned by EBMR (and to which the improvements above were made) at a cost of $72,000 per year for 6 years ($432,000 total). The leasing cost will be paid by the forgiveness by the Company of $432,000 of the Loan Balance owed by EBMR.
• EBMR will enter into a consulting agreement with the Company pursuant to which the EBMR will manage the production of the Company’s natural health products and pass on know how to the Company related to the production of those products. The services will be provided for a monthly consulting fee of $3,000 over a period of 6 years. The aggregate consulting fees of $216,000 will be paid through the forgiveness by the Company of $216,000 of the Loan Balance owed by EBMR. As part of this process, the Company will develop the expertise necessary to produce natural health products on its own, which will reduce future production costs.
• The Company and EBMR are parties to a management and administrative services agreement dated December 12, 2012 as amended by an amending agreement dated June 1, 2014 (the “Management Agreement”), pursuant to which EBMR provides management services to the Company. EBMR has agreed to reduce the management fees under the Management Agreement by 15% over a 6 year period. This amounts to a reduction of $227,700 over this period. This amount of the Loan Balance will be forgiven by the Company as a result of said reduction in management fees.

EBMR holds 69.5% of the issued and outstanding common shares of the Company. The proposed settlement of the Loan Agreement constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company is relying on the exemptions from the formal valuation and minority approval requirements contained in Sections 5.5(b) and 5.7(1)(a) of MI 61-101, on the basis that the Company is not listed on specified markets and the fair market value of the transaction does not exceed 25% of the Company’s market capitalization.

About Eastwood Bio-Medical Canada, Inc.:
The Company is a Vancouver based biotechnology company whose Eleotin® brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.

Eleotin® was initially developed by the scientists at the Julia McFarlane Diabetes Research Center (JMDRC) at the University of Calgary in Alberta, Canada. The JMDRC is a leader in research on the cause, cure, and prevention of Type I and Type II diabetes. After the initial development by the JMDRC, research and development were continued by Eastwood Bio-medical Research Inc., the Company, and other institutions around the world, including Tsinghua University of the People’s Republic of China. Eleotin® products have been endorsed by thousands of doctors and diabetes associations around the globe.

More information on Eastwood Bio-Medical Canada Inc., can be found on the website www.eleotin.ca.

For further information, please contact:

Eastwood Bio-Medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
Telephone: (604) 247-2100

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Renee

08/01/18 10:15 AM

Post #10

EBM: Eastwood Bio-medical Canada Inc. added to the OTC as EWOOF:

(no ticker change since EBM is the primary ticker for trading in Canada)

http://otce.finra.org/DLAdditions

Claude233

07/23/18 1:55 PM

Post #9

EASTWOOD BIO-MEDICAL CANADA INC.

NEWS RELEASE

EASTWOOD BIO-MEDICAL CANADA INC. UNAWARE OF ANY MATERIAL CHANGE

FOR IMMEDIATE RELEASE

July 23, 2018 – Richmond, British Columbia – At the request of IIROC, Eastwood Bio-medical Canada Inc. (TSX-V: EBM) (the “Company”) wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.

The Company is a Vancouver based biotechnology company whose Eleotin® brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain assumptions, estimates, and other forward-looking statements regarding future events. Such forward-looking statements involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.

For further information, please contact:
Eastwood Bio-medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
Telephone: (604)-247-2100

www.eleotin.ca

Claude233

06/29/18 3:16 PM

Post #8

EASTWOOD BIO-MEDICAL CANADA INC.
#1130 - 4871 Shell Road
Richmond, British Columbia
V6X 3Z6

TSX-V: EBM

NEWS RELEASE

Eastwood Bio-Medical Canada Enters Binding Terms for Asian Exports

June 28, 2018 – Vancouver, British Columbia – Eastwood Bio-Medical Canada Inc. (TSX-V: EBM) (the “Company”) is pleased to announce the Company has agreed on binding terms with an Asian distribution company for a purchase order, the first segment of which will total $1.05 million USD. Announcements regarding the shipments and ensuing orders are expected to follow.

This initial segment of the purchase orders will include products already well established in Canada, such as Eleotin® Kalimera and Eleotin® Ma5, and also new ‘advanced’ formulas made especially for Asian markets.

Eastwood Bio-medical Research Inc. fully supports the transaction. This initial segment of the purchase order is expected to be reflected in the next interim statements, for Q3 or Q4 2018, and is expected to result in a 900% increase in revenues compared to the same quarters last year.

Yunji Kim, President and CEO, commented, “We are extremely pleased to have reached this milestone. Our new manufacturing capabilities allow us to finally start producing highly advanced and complex products with the best quality and process control on a meaningfully larger scale. The manufacturing capacity was limited to less advanced products in the past. It was one of the factors that limited our growth. Our entering into this agreement proves that we are confident that we are no longer being bound by such production limitations.

Even though we have already had an exciting and growing line of products, including products that have been authorized by Advertising Standards Canada (ASC) to be marketed as the ‘World’s #1 Doctor Recommended Natural Source Healthy Blood Glucose Promoting Product available in Canada.’, our revenue has been extremely limited by these technical production limitations. Understandably, a few analysts and experts have been puzzled as to why the revenues were so small, when the products were proven to have attractive results. I hope that a continuing stream of larger scale transactions will soon put to rest all the remaining puzzles and scepticisms.

It is the first order to Asia of this size that takes advantage of the new capabilities. The Asian market for these products are already vast and growing explosively rapidly. The Company has begun negotiating distribution terms with several other Asian companies, as well as additional orders from the above mentioned company.

Having gained critical manufacturing capacities for advanced products and begun negotiations with major distributors, I am looking forward to our company’s continuing bright performance and growth in the future.”

About Eastwood Bio-Medical Canada, Inc.:
The Company is a Vancouver based biotechnology company whose Eleotin® brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.

Eleotin® was initially developed by the scientists at the Julia McFarlane Diabetes Research Center (JMDRC) at the University of Calgary in Alberta, Canada. The JMDRC is a leader in research on the cause, cure, and prevention of Type I and Type II diabetes. After the initial development by the JMDRC, research and development were continued by Eastwood Bio-medical Research Inc., the Company, and other institutions around the world, including Tsinghua University of the People’s Republic of China. Eleotin® products have been endorsed by thousands of doctors and diabetes associations around the globe.

More information on Eastwood Bio-Medical Canada Inc, can be found on the website www.eleotin.ca.

For further information, please contact:

Eastwood Bio-Medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
Telephone: (604) 247-2100

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Claude233

06/07/18 6:47 PM

Post #7

EASTWOOD BIO-MEDICAL CANADA INC. BEGINS DISCUSSIONS FOR EXPORT AGREEMENT

June 7, 2018 – Richmond, British Columbia – Eastwood Bio-medical Canada Inc. (TSX-V: EBM) (the “Company”) is pleased to announce the Company has begun negotiating an export agreement with a third party company based in Asia. The contemplated deal would involve the third party purchasing unspecified volumes of five unique Eleotin® products developed for the Asian market.
The third party expressed preference for purchasing Eleotin® products company from the Company instead of Eastwood Bio-Medical Research Inc. (“EBMR”), a major shareholder of the Company. EBMR has expressed a willingness to negotiate the transfer of certain Asian distribution rights to the Company.
All agreements will be subject Exchange and Board approval as necessary.
For further information, please contact:
Eastwood Bio-medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
Telephone: (604)-247-2100

www.eleotin.ca

Forward-Looking Statement:
This email contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company, including expectations and assumptions concerning TSXV approvals. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Certain factors, which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Claude233

05/24/18 3:14 PM

Post #6

EASTWOOD BIO-MEDICAL CANADA INC. ENGAGES NAI INTERACTIVE LTD. TO BUILD MARKET VISIBILITY

May 22, 2018 – Richmond, British Columbia – Eastwood Bio-medical Canada Inc. (TSX-V: EBM) (the “Company”) has engaged NAI Interactive Ltd. (NAI) to conduct a twelve-month market visibility program.

Yunji Kim, President and CEO, stated, “We have always had fantastic products the market craves. For example, Advertising Standards Canada authorized us in 2014 to market Eleotin® Bentley, our flagship product, as the ‘World’s #1 Doctor Recommended Natural Source Healthy Blood Glucose Promoting Product available in Canada.’ We have also won prestigious international awards, and been endorsed by numerous diabetes associations.

But, our limited production capacity prevented us from taking full advantage of this market demand. The recent acquisition of new manufacturing capabilities, however, would finally resolve this issue for us.

With our manufacturing capability problem behind us, and with NAI’s expertise working for us, we look forward to sharing with a wider audience our rich history and our future development and growth.

We have acquired thirty five new Natural Product Numbers in 2017 and 2018. We will continue to add scientifically researched, new and exciting natural health products.”

For further information, please contact:
Eastwood Bio-medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
Telephone: (604)-247-2100

www.eleotin.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Claude233

05/15/18 4:49 PM

Post #5

EASTWOOD BIO-MEDICAL CANADA ADDRESSES RECENT RISE IN SHARE PRICE

May 15, 2018 – Richmond, British Columbia – Eastwood Bio-medical Canada Inc. (TSX-V: EBM) (the “Company”) comments on the recent rise in share price. The shares traded to a high of $0.17 on May 15 compared to a low of $0.065 in April of 2018. Yunji Kim, President and CEO, stated that management of the Company is not aware of any new material information regarding the operations of the Company that might explain the recent price movement.

In April of 2018 the Company announced the launch of various new products, which is consistent with past announcements of ongoing operations. The Company also confirmed it had acquired manufacturing capabilities pursuant to the exercise of an option agreement that was previously announced in June of 2016.

The Company also announces that Louis Picco resigned from the Company’s Board of Directors on April 12, 2018, and the Company thanks him for his contributions.

For further information, please contact:

Eastwood Bio-medical Canada Inc.
Yunji Kim, President and Chief Officer
Telephone: (604)-247-2100

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.